Home/Rare Diseases/Charcot-Marie-Tooth Disease
Neurological & Neuromuscular

Charcot-Marie-Tooth Disease

Affects approximately
1 in 2,500 people

Also known as: CMT, hereditary motor sensory neuropathy, HMSN

Charcot-Marie-Tooth Disease

About Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth disease (CMT) is a group of inherited peripheral neuropathies affecting motor and sensory nerves, making it one of the most common inherited neurological disorders. Over 80 different genetic mutations have been identified, resulting in heterogeneous presentations and progression rates. CMT1 (demyelinating form) involves abnormal myelin (the insulation around nerves); CMT2 (axonal form) involves damage to the nerve fibers themselves. The condition typically begins with progressive weakness and atrophy of distal leg muscles, causing foot drop and difficulty walking. Hand weakness develops later. Sensory loss progresses from distal to proximal. While CMT is progressive, progression is typically slow, and most individuals maintain ambulation throughout life, though some require assistive devices. Pain can be significant for some patients. The diagnosis requires clinical assessment, genetic testing, and sometimes nerve conduction studies or muscle biopsy.

Common Symptoms

  • Foot weakness causing high arches and hammertoes
  • Distal leg muscle atrophy creating inverted bottle-leg appearance
  • Difficulty walking or running due to foot drop
  • Hand weakness and clumsiness
  • Loss of sensation in feet and hands
  • Scoliosis in some patients

Who It Affects

Usually manifests in childhood or early adulthood, though some forms present later. Affects males and females equally. Multiple genetic forms with varying inheritance patterns (autosomal dominant, recessive, or X-linked).

Getting Involved in Clinical Trials

Clinical trials for CMT are evaluating therapies targeting specific CMT genetic subtypes, including those for CMT1A (PMP22 overexpression), CMT1B, and CMT2A mutations. Antisense oligonucleotides and gene therapy approaches are in development. The Charcot-Marie-Tooth Association provides comprehensive trial information and patient support. Genetic testing to identify the specific CMT subtype is important, as several emerging therapies target specific mutations. Therapies like PMP22-targeting antisense oligonucleotides show promise for CMT1A. Regular neurological monitoring, physical therapy, and appropriate assistive devices (braces, walkers) can slow functional decline and improve quality of life.

Trusted Sources

Active Clinical Trials for Charcot-Marie-Tooth Disease

Finding trials for Charcot-Marie-Tooth Disease...

Related Neurological & Neuromuscular Conditions

Neurological & Neuromuscular

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...

Neurological & Neuromuscular

Spinal Muscular Atrophy

Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...

Neurological & Neuromuscular

Myasthenia Gravis

Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...